BLUE earnings

- 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence

bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,

Actions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET Following a comprehensive review of its operations, bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the Company's workforce of approximately 25%. The Company's cash flow break-even tar

- 27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA); anticipate approximately 85 patient starts across the portfolio as LYFGENIA patient starts accelerate in the second half of 2024 - - Second quarter 2024 net revenue of $16.1 million - - Cash runway into Q2 2025 based on current operating plans and cash on hand - - Management to host conference call today, August 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported second quarter results and business highlights for the quarter ended June 30, 2024, including recent commercial and operational progress. "We are seeing clear evidence that our commercial launch

bluebird bio, Inc. (NASDAQ:BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 2776050. To access the live webcast, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the event. About bluebird bio, Inc. bluebird bio is pursuing curative gene the

- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First quarter 2024 net revenue of $18.6 million - - Management to host conference call today, May 9, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress. "bluebird has built a solid commercial gene therapy foundation, with an unparalleled network of qualified treatment centers (QTCs), proven

bluebird bio, Inc. (NASDAQ:BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 9768329. In addition, members of the management team will participate in the following upcoming investor conferences: BofA Securities 2024 Health Care Conference, Thursday, May 16, at 10:00 a.m. PT (1:00 p.m. ET) in Las Vegas, NV Goldman Sachs 45th Annual Global Healthcare Conference, Wednesday, June 12, at 11:20 a.m. ET in Miami Beach, FL To access the

- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital - - 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid - - 62 qualified treatment centers (QTCs) activated - - Full year 2023 revenue of $29.5 million with $7.8 million generated in the fourth quarter - - Management to host conference call today, March 26, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial result

bluebird bio, Inc. (NASDAQ:BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET. To access the live conference call via telephone, please register at this link to receive a dial in number and unique PIN. The live webcast of the call may be accessed by visiting the "Events & Presentations" page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event. About bluebird bio, Inc. bluebird bio is pursuing curative gene therapies to give patient

Severe vaso-occlusive events were eliminated for 94% (30/32) of evaluable patients and all VOEs were eliminated for 88% (28/32) of evaluable patients between 6 and 18 months post-infusion LYFGENIA is the most deeply studied gene therapy for sickle cell disease with the most patients treated and longest follow-up Management to host conference call today, December 8, 2023, at 4:15 p.m. ET bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or "bluebird") today announced the U.S. Food and Drug Administration (FDA) has approved LYFGENIA™ (pronounced as ‘lif-JEN-ee-uh') (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older

- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 22 patient starts across both programs to date – - Ended quarter with $227M in cash, cash equivalents, marketable securities and restricted cash – - Company entered into advance agreement to sell priority review voucher, if granted, for $103 million; potential non-dilutive capital would strengthen cash position – - Management to host conference call today at 8:00AM ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the third quarter ended September 30, 2023, including recent commercial and operational progress, and regulatory updates. "

bluebird bio, Inc. (NASDAQ:BLUE) announced today that it will host a conference call to discuss third quarter 2023 financial results and business updates on Tuesday, November 7 at 8:00 a.m. ET. To access the call via telephone, please register at this link https://edge.media-server.com/mmc/p/cq4tzukh to receive a dial in number and unique PIN to access the live conference call. The live webcast of the call may be accessed by visiting the "Events & Presentations" page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event. About bluebird bio, Inc.

- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 16 patient starts across both programs to date – - Biologics License Application (BLA) for lovo-cel for sickle cell disease accepted for FDA priority review; PDUFA goal date December 20, 2023 - - Ended quarter with $291M in cash, cash equivalents, marketable securities and restricted cash – - Management to host conference call on Q2 earnings and commercial launch progress today August 8, 2023 at 8:00AM ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the second quarter ended June 30, 2023, including recent commercial and operational pro

bluebird bio, Inc. (NASDAQ:BLUE) today announced it will hold a conference call to discuss second quarter 2023 financial results and provide a commercial update on Tuesday, August 8 at 8:00 a.m. ET. In addition to providing an overview of the business, the conference call will highlight the Company's ongoing commercial launches of SKYSONA® and ZYNTEGLO® and the market opportunity for lovo-cel. To access the call via telephone, please register at this link https://register.vevent.com/register/BI4fa1d86317c74333813f6827624e43ae to receive a dial in number and unique PIN to access the live conference call. The live webcast of the call may be accessed by visiting the "Events & Presentations

SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease Management team to host conference call Monday, September 19, at 8:00 a.m. ET bluebird bio, Inc. (NASDAQ:BLUE) today announced the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of SKYSONA® (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). The Company also confirmed that the previous clinical hold on the eli-cel clinical development program has been lifted. CALD is a rar

ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels Management team to host conference call Thursday, August 18 at 8:00 am ET bluebird bio, Inc. (NASDAQ:BLUE) today announced the U.S. Food and Drug Administration (FDA) has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. "The FDA approval of ZYNTEGLO offers people with beta-thalassemia the possibility of fr

Expected to deliver up to $160 million in cost savings over the next two years and extend the Company's cash runway through pivotal upcoming milestones in the first half of 2023 Management team to host conference call today, April 5, 2022 at 8:00 am ET Following a review of its strategic priorities, bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company is initiating a comprehensive restructuring intended to deliver up to $160 million in cost savings over the next two years. bluebird intends to sharpen its focus on near-term catalysts, including anticipated FDA approvals for its gene therapies for beta-thalassemia and cerebral adrenoleukodystrophy in 2022, and the potential su

- On track to complete planned business separation in 4Q 2021; each company launching with approximately 24 months of runway following separation – - Severe genetic disease (SGD) business to scale back operations in Europe to focus on the U.S. market - - ABECMA generates strong performance in first quarter of U.S. launch – - FDA has placed studies of elivaldogene autotemcel (eli-cel, Lenti-D™) for cerebral adrenoleukodystrophy (CALD) on clinical hold following safety report; other SGD and oncology programs not impacted – - Ended quarter with $942M in cash, cash equivalents, and marketable securities - - Company to host conference call today, August 9, 2021 at 8:00 am ET – bluebird

bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the quarterly update on Monday, August 9, 2021 at 8 a.m. ET. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 9698691. Additionally, members of the management team will present at the following upcoming investor conferences: 2021 Wedbush PacGrow Healthcare Conference, Wednesday, August 11, at 12:00 p.m. ET as part of the panel titled Miss Con-GENE-iality

Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong Commercial Performance, Including Opdivo's Return to Growth and Momentum across New Product Portfolio Achieves Significant Regulatory and Clinical Milestones across Product Pipeline Further Strengthens Pipeline through Disciplined Business Development Agreements, including with Agenus and Eisai Adjusts GAAP and Reaffirms Non-GAAP EPS Guidance for 2021 Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, co